Mylan and Biocon submit BLA for biosimilar trastuzumab

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MYLAN N.V. and Biocon Ltd. announced submission of Mylan’s biologics license application for MYL-1401O, biosimilar trastuzumab, to the FDA through the 351(K) pathway. This product is a proposed biosimilar to branded trastuzumab, which is indicated to treat certain HER2-positive breast and gastric cancers. Mylan and Biocon believe that this has the potential to be the...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login